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During gastrulation of the amphibian embryo, speci-
fication of the three germ layers, endo-, ecto-, and
mesoderm, is regulated by maternal and zygotic
mechanisms. Although it is known that mesoderm
specification requires the cooperation between
TGF-b signaling and p53 activity and requires mater-
nal factors, essential zygotic factors have been
elusive. Here, we report that the Zn-finger protein
XFDL156 is an ectodermal, zygotic factor that sup-
presses mesodermal differentiation. XFDL156 over-
expression suppresses mesodermal markers, and
its depletion induces aberrant mesodermal differen-
tiation in the presumptive ectoderm. Furthermore,
we find that XFDL156 and its mammalian homologs
interact with the C-terminal regulatory region of
p53, thereby inhibiting p53 target gene induction and
mesodermal differentiation. Thus, XFDL156 actively
restricts mesodermal differentiation in the presump-
tive ectoderm by controlling the spatiotemporal
responsiveness to p53.
INTRODUCTION
During early vertebrate embryogenesis, three germ layers, the
ectoderm, mesoderm, and endoderm, are formed from pluripo-
tent cells at the onset of gastrulation. In the Xenopus embryo,
germ-layer specification is substantially influenced bymaternally
deposited positional information. Along the animal-vegetal axis,
the ectoderm and endoderm arise from the animal cap and
vegetal pole regions, respectively, while the mesoderm forms
in the marginal zone (Heasman, 2006). The early animal cap is
pluripotent and the mesoderm is induced in pluripotent cells by
endoderm-derived mesodermalizing signals (e.g., Nodal/Xnrs;
Schier, 2003), which are regulated by vegetally localized mater-
nal factors such as VegT (Smith, 1997). In addition, under the
maternal influence, the presumptive mesoderm itself expresses
mesoderm-inducing Nodal-related factors, such as Derriere
(Sun et al., 1999), which reinforce the mesodermal specification
(Eimon and Harland, 2002).
In contrast, it has remained elusive whether the ectodermal
specification of pluripotent cells is an active or passive process
(Wardle and Smith, 2006). A recent report on the maternal factor878 Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc.Ectodermin has suggested that it actively prevents presumptive
ectodermal cells from undergoing mesodermal differentiation.
Ectodermin acts as a RING-type E3 ubiquitin ligase that targets
and degrades Smad4, thereby attenuating the responsiveness
of animal cap cells to mesoderm-inducing TGF-b-family signals
(Dupont et al., 2005). In addition, previous studies indicated that
mesodermal suppression in the animal cap may also involve two
other maternally expressed genes, Coco and Sox3, which can
negatively modulate TGF-b signals (Bell et al., 2003; Zhang
and Klymkowsky, 2007).
In contrast to thematernalmechanism, the zygoticmechanism
for ectodermal specification has remained less clear. In amphib-
ian ectodermal development, classic explant studies have dem-
onstrated the importance of zygotic mechanisms in the stage-
specific loss of competence for mesodermal differentiation.
Xenopus animal cap cells become committed to the ectodermal
fate by the mid-gastrula stage and stop responding to mesoder-
mal inducers such as TGF-b-family molecules that activate the
Smad2/Smad4 pathway (Steinbach et al., 1997; Grimm and
Gurdon, 2002). This phenomenon cannot be easily explained
by the involvement of maternal factors such as Ectodermin
(Dupont et al., 2005). A previous study showed that overexpres-
sion of constitutively active Notch can elongate the competence
period of the animal cap for mesodermal induction (Coffman
et al., 1993). However, whether this mechanism plays a role in
normal development remains unclear at present. In addition, al-
though a few transcription factors expressed on the animal side
have been recently shown to promote ectodermal differentiation,
the molecular mechanisms behind these phenomena are still
understood rather fragmentally (Mir et al., 2007; Snir et al., 2006).
In this study, we performed a functional screen for ectoderm-
specific zygotic genes involved in this process and isolated a
zygotic zinc (Zn)-finger nuclear factor, XFDL156, that actively
suppresses mesodermal differentiation in the presumptive
ectoderm.
RESULTS
Identification of a Zygotic Nuclear Factor that Inhibits
Activin-Induced Mesodermal Differentiation
At the beginning of this study, we observed that microinjection of
mRNA from stage 11.5 animal caps suppressed mesodermal
differentiation induced by Activin (a TGF-b-family factor) more
efficiently than did the injection of mRNA from stage 8.5 tissues
(Figures S1A-S1D available online), suggesting that zygotic tran-
scripts in the gastrula animal cap negatively modulate the cell’s
competence for mesodermal induction. We therefore con-
structed an expression cDNA library from stage 11.5 animal cap
mRNA for a functional screen (Figure 1A). Two hundred pools of
96 plasmid clones were transcribed in vitro and injected into all
the animal blastomeres of 8-cell embryos. Animal cap explants
were prepared at stage 8.5, treated with Activin until stage 11,
and analyzed for the expression of the early mesoderm marker
gene Brachyury (Xbra; Smith, 1997) by quantitative RT-PCR
(q-PCR). Twenty pools of mixed clones reproducibly suppressed
Xbra expression (e.g., #105 in Figure 1B) and were subjected to
sib screening. Finally, we identified five individual clones with
mesoderm-inhibiting activity (Figure 1C). They encoded
XFDL156 (#105-F5), HMG-X (Kinoshita et al., 1994), an E2 ubiqui-
tin-conjugating enzyme (GenBank accession #BC088818), a pre-
sumptive RNA-binding protein related to SR-p38 (Liu and Har-
land, 2005), and an SH3-containing protein (Tosoni et al., 2005).
Among these, the function of the Zn-finger protein XFDL156
(XFDL, hereafter; containing multiple Kru¨ppel-type Zn fingers)
has been unexplored (Bellefroid et al., 1997; Figure 1D). Interest-
ingly, XFDL expression is observed transiently (Figure 1E). XFDL
first appeared at the late blastula stage diffusely in the animal
cap region (Figures 1F and 1G). At the early gastrula stage,
strong XFDL expression was detected widely in the presumptive
ectoderm (Figures 1H and 1I; both in the superficial and sensorial
layers). XFDL expression at late gastrulation was limited to a ros-
tral part of the neuroectoderm (Figures 1E and 1J). Immunostain-
ing showed that XFDL was mainly located in the nuclei of animal
cap cells (Figure 1K; Figures S1E–S1J for controls).
In the animal cap assay, overexpression of XFDL inhibited the
Activin-induced expression of another early mesodermal gene,
Mix.2 (Chen et al., 1996, 1997), in addition to Xbra expression,
suggesting that XFDL interferes with the differentiation of meso-
derm from pluripotent cells (Figures 1L–1Q).
Specific Inhibition of Mesodermal Differentiation
but Not of Neural or Endodermal Induction by XFDL
Injection of XFDL did not reduce the expression of the endoder-
mal markers Sox17a (Wardle and Smith, 2006) and Xenf (Naka-
tani et al., 2000) in Activin-treated animal caps, indicating that
XFDL overexpression has little effect on early endodermal induc-
tion (Figures 2A and S2A). XFDL inhibited the induction of neither
Xnr-1 by Activin nor Siamois by Wnt8 in the animal cap assay
(Wardle and Smith, 2006; Figures S2A and S2B). XFDL injection
did not suppress the induction of Sox2 by Chordin in the animal
cap (Sasai et al., 1994; Mizuseki et al., 1998; Figure 2B), showing
that XFDL does not inhibit neural differentiation.
XFDL strongly suppressed Xbra (86%, n = 44; Figures 2C and
2D) and Mix.2 (78%, n = 45; Figures 2E and 2F) in the embryo.
XFDL also decreased the expression of Chordin (dorsal meso-
derm, 100%, n = 24; Figures 2G and 2H) and Vent1 (Gawantka
et al., 1995; ventral mesoderm, 89%, n = 27; Figures 2I and 2J),
showing that mesodermal differentiation was generally impaired.
In contrast, the in vivo expression of Sox17a (n = 56; Figures 2K
and 2L), Sox2 (n = 30; Figures 2M and 2N), and Xnr-3 (Smith
et al., 1995; n = 22, Figures 2O and 2P) was largely unaffected.
Interestingly, the expression of Foxi1a (Matsuo-Takasaki et al.,
2005; a pan-ectodermal marker at this stage) and Foxi1e (Mir
et al., 2007; another ectodermal marker) was expanded intothe marginal zone by XFDL (Figures 2Q and 2R and not shown).
No substantial suppression of the mesodermal marker was ob-
served when unrelated multiple Zn-finger factors, SalF and Tsh3
(Onai et al., 2004, 2007), were overexpressed (Figures 2S and
2T). Thus, XFDL blocks not only in vitro mesodermal induction
by exogenous Activin but also the endogenous programof in vivo
mesodermal development in a germ-layer-specific manner.
Knockdown of XFDL Induces Aberrant Mesodermal
Differentiation in the Presumptive Ectodermal Tissue
Injection of XFDL-MO experiments (see Figure S1K for controls)
expanded Xbra expression toward the animal pole of the gas-
trula embryo (69%, n = 80; Figures 3A–3C). Thismarked increase
in Xbra expression was reversed by coinjection of XFDL (coding
region only; no increase in 66%, n = 56; Figure 3D). Strong induc-
tion was also observed for another pan-mesodermal marker,
zygotic VegT (Figures 3E and 3F), suggesting that the knock-
down of XFDL desuppresses the expression of mesodermal
markers in the animal region.
In contrast, XFDL-MO injection reduced the Sox2 expression
(94%, n = 34; Figures 3G and 3H), suggesting that the expansion
of mesodermal marker expression occurred at the expense of
neural induction in the ectoderm. Unlike the mesodermal and
neural markers, expression of the endodermal marker Sox17a
was not affected (n = 25; Figures 3I and 3J).
Explant experiments showed that XFDL-MO induced meso-
dermal marker expression (Xbra, VegT, and Mix.2) in the animal
cap without Activin treatment (Figure 3K). In contrast, Chordin-
induced Sox2 expression in vitro was reduced by XFDL-MO in
a dose-dependent manner (Figure 3L).
These findings suggest that XFDL is essential for the suppres-
sion of aberrant mesodermal differentiation in the presumptive
ectodermal tissues.
XFDL Inhibits Mesodermal Gene Activation
by p53 and Its Coactivator
XFDL does not inhibit Activin from inducing endodermal differen-
tiation (Figures 2A and S2A), suggesting that the TGF-b signaling
pathway per se is active in XFDL-overexpressing cells. Consis-
tent with this idea, XFDL neither reduced the level of Smad2
proteins nor interfered with their phosphorylation (Figure S2C).
In addition, injection of neither XFDL mRNA nor XFDL-MO sub-
stantially inhibited the nuclear accumulation of phosphorylated
Smad2 upon Activin treatment (arrows in Figure S2D).
Recent studies have revealed a critical role of p53 in mesoder-
mal determination. p53 binds to the promoter of early mesoder-
mal genes such asMix.2 and cooperates with the Smad pathway
(Cordenonsi et al., 2003; Takebayashi-Suzuki et al., 2003). p53 is
also implicated as a node point for the integration of the TGF-b
and Fgf/MAPK signaling pathways (Cordenonsi et al., 2007).
However, relatively little is known about the restriction of the
p53 function in the presumptive ectoderm.
Consistent with previous reports, p53 overexpression strongly
expanded the expression of the mesodermal markers Xbra
and Mix.2 toward the animal pole (47%, n = 62 for Xbra; 38%,
n = 58 for Mix.2; Figures 4B and 4E). Interestingly, coinjection
of XFDL completely reversed these inductions (suppressed in
100%, n = 40 for each probe; Figures 4C and 4F), indicatingCell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc. 879
Figure 1. Functional Screening for Zygotic Nuclear Factors that Inhibit Activin-Induced Mesoderm Differentiation in the Animal Cap
(A) Schematic of the functional screen.
(B) q-PCR analysis for Xbra expression in Activin-treated animal caps injected with pooled mRNAs. In this experiment, pool #105 substantially suppressed Xbra
expression.
(C) Example of the isolation of a clone (#105-F5) that reduced Xbra expression. Each clone from the #105-F pool (12 clones) was analyzed as in (B).
(D) The structure of XFDL. Nuclear localization signals (gray boxes); zinc-finger motifs (black boxes).
(E) XFDL expression analyzed by q-PCR. Numbers represent the stages of embryos. E: unfertilized egg. (F–J) Whole-mount in situ hybridization of XFDL expres-
sion in 8-cell (F), late blastula (stage 9.5; G), early gastrula (stage 10.5; H and I), and mid-gastrula (stage 12; J) embryos. (I) Sagittal section. An: animal, Veg:
vegetal, A: anterior, P: posterior, D: dorsal, V: ventral. (K) Immunohistochemistry using an anti-XFDL156 antibody (red) in animal cap cells at stage 10.5. DAPI
staining (green).
(L–Q) Expression of Xbra (L–N) andMix.2 (O–Q) in animal cap explants analyzed by in situ hybridization. Animal caps given injections of control (L, M, O, and P;
400 pg/cell) or XFDL (N and Q; 400 pg/cell) mRNAs were prepared at the mid-blastula stage (stage 8.5) and cultured until siblings reached stage 11 without
(L and O) or with (M, N, P, and Q) 5 ng/ml Activin.880 Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc.
Figure 2. Specific Inhibition of Mesodermal Differentiation by XFDL
(A) q-PCR analysis for Xbra (top), Mix.2 (middle), and Sox17a (bottom) expression. The four animal blastomeres at the 8-cell stage were injected with control
mRNA (400 pg/cell; lanes 1 and 2) or 100 pg/cell (lane 3), 200 pg/cell (lane 4), or 400 pg/cell (lane 5) of XFDL mRNA. Animal caps (excised at stage 8.5) were
then cultured without (lane 1) or with 5 ng/ml Activin (lanes 2–5) until siblings reached stage 11.
(B) q-PCR analysis for Sox2 expression. Chordin (50 pg/cell; lanes 2–5) and increasing amounts of XFDLmRNAs were coinjected and analysis was performed as
in (A).
(C–R) In situ hybridization analysis of the embryos injected with XFDL mRNA. Control embryos (C, E, G, I, K, M, O, and Q) or embryos given XFDL mRNA
(400 pg/cell) by injection at the 4-cell stage (D, F, H, J, L, N, P, and R) were harvested at stage 10.5 (C–L and O–R) or stage 11.5 (M and N) and analyzed by
the indicated probes. Arrowheads, the dorsal and ventral blastopore lips; bracket, the marginal zone (see Xbra expression in panel C).
(S and T) Embryos injected with SalF (400 pg/cell; S) or Tsh3 (400 pg/cell; T) were analyzed at stage 10.5 by in situ hybridization using the Xbra probe.that XFDL counteracts the p53 activity. To further analyze this
antagonism, we next performed animal cap assays. Mix.2 ex-
pression was strongly increased in the animal cap by coinjection
of p53 and p300 (encoding a coactivator of p53; Gu et al., 1997;
Lill et al., 1997) (Figure 4G). This p53/p300-induced elevation of
Mix.2 expression was inhibited by coinjection of XFDL in a dose-
dependent manner (Figure 4G, lanes 3–5).
We next performed coinjection assays of XFDL-MO and
p53-MO (Figures 4H-4L). As reported previously (Cordenonsi
et al., 2003; Takebayashi-Suzuki et al., 2003), p53-MO inhibited
mesodermal differentiation in the embryo (Figure 4J). Coinjection
of two MOs caused a phenotype indistinguishable from that
caused by p53-MO alone (Figure 4K; n = 18, 100%). In addition,
coinjection of p53-MO suppressed mesodermal marker induc-
tion by XFDL-MO in the animal cap (Figure 4L). These findings
suggest that XFDL’s function on mesodermal differentiation is
largely dependent on p53 activity.We next examined the effect of XFDL on p53/p300 activity in
a luciferase assay using the Mix.2 promoter, which contains a
p53-response element as well as an Activin-response element
(ARE; Smad4/Fast1-binding site; Chen et al., 1996, 1997) (Fig-
ures 4M and 4N). XFDL caused a dose-dependent suppression
of p53/p300 activity (Figure 4O, lanes 3–5). Moreover, a similar
suppression was observed even when the ARE was mutated in
the Mix.2 promoter (Figures 4P and 4Q). We next performed a
luciferase assay using p53-luc, which contains a p53-specific
promoter that consists of 14 repeats of a p53-binding element
(derived from the Muscle Creatine Kinase promoter; Zambetti
et al., 1992) and no ARE (Figure 4R). XFDL inhibited the p53/
p300-induced elevation of luciferase activity with this promoter
(Figure 4S, lanes 3–5), as was seen with theMix.2 promoter (Fig-
ures 4O and 4Q). In contrast, the Activin-induced activity of
DE(4x)-luc (a pure Activin/Smad2-responding reporter; Watabe
et al., 1995) was not affected by XFDL (Figure 4T).Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc. 881
Figure 3. Mesodermal Conversion Induced
by XFDL Knockdown in the Animal Cap
(A–J) In vivo effects of XFDL-MO. Control embryos
(A, E, G, and I) or embryos given 50 ng/cell of
XFDL-MO (25 ng/cell of XFDL156-MO + 25 ng/cell
of XFDL141-MO for the short minor splicing vari-
ant; see Supplemental Experimental Procedures;
B, F, H, and J), two five-base-mismatched MOs
(25 ng/cell of each; C), or 50 ng/cell of XFDL-
MO + XFDL mRNA (100 pg/cell; D) by injection
were harvested at the early gastrula stage and an-
alyzed by in situ hybridization using the indicated
probes. Sectioned embryos are shown in (E) and
(F). Brackets (in panels A and B) and arrowheads
(in panels E and F) indicate the expression areas
of Xbra and VegT, respectively.
(K) q-PCR analysis for the expression of mesoder-
mal marker genes. XFDL-MO (50 ng/cell) was
injected at the 8-cell stage. Animal caps were pre-
pared at stage 8.5, cultured until siblings reached
stage 10.5, and analyzed by q-PCR.
(L) Chordin-induced neural differentiation was
attenuated by XFDL-MO in the animal cap. Control
(10 pg/cell; lane 1) or Chordin (10 pg/cell; lanes
2–4) mRNAs were injected with 12.5 ng/cell (lane
3) or 50 ng/cell (lane 4) of XFDL-MO. Explants
were prepared at stage 8.5 and harvested at stage
11.5. Sox2 expression was analyzed by q-PCR. In
(K) and (L), the expression of each gene in the
control animal cap was defined as 1.We next tested whether XFDL interfered with p53 activity in a
different biological assay, that is, apoptosis induction by p53
(Bode and Dong, 2004). The p53-induced apoptosis was sup-
pressed by coinjection of XFDL (Figures S3B and S3C). In con-
trast, a dominant-negative Fast1 (Fast1-EnR, which blocks
the Smad/Fast1 pathway; Watanabe and Whitman, 1999;
Figure S3D) did not reverse the increase. Conversely, XFDL-
MO increased the apoptosis in the animal cap (Figure S3E).
This increased apoptosis was reversed by p53-MO but not by
Fast1-EnR (Figures S3F and S3G). Thus, XFDL’s effect on apo-
ptosis appears to be related to p53 but not directly to the
Smad/Fast1 pathway.
Taken together, these findings demonstrate that XFDL is
capable of antagonizing p53 functions in early Xenopus tissues.
XFDL Depletion Prolongs the Competence
Period for p53-Triggered Mesodermal Differentiation
in the Animal Cap
We next examined mesodermal differentiation in response to
temporally controlled p53 activity in the animal cap using a hor-
mone-inducible construct of p53, GR-p53 (Takebayashi-Suzuki
et al., 2003). When GR-p53-injected animal caps were treated
with dexamethazone (Dex) from stage 8.5, expression of the me-
sodermal markers Mix.2 and Bix3 (Trindade et al., 2003) was
substantially increased (blue columns in Figures 4U and S5,
lane 3). Little increase, if any, in the expression of themesodermal882 Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc.genes was seen when Dex treatment was started at stage 11
(equivalent) in GR-p53-injected animal caps (blue columns in
Figures 4U and S5, lane 3). Thus, the temporal window for high
responsiveness to p53 activity terminates by the early gastrula
stage equivalent in the animal cap. Interestingly, when XFDL-
MO was coinjected, the responsiveness to Dex-induced p53
activity was maintained in the stage 11 animal cap (red columns
in Figures 4U and S5, lane 6). These findings demonstrate that
XFDL is required, at least in part, for the loss of cellular compe-
tence for p53-dependent mesodermal differentiation in the
gastrula animal cap.
XFDL Directly Interacts with p53 and Reduces
p53’s Binding to Its Target DNA Site
We next studied whether XFDL and p53 physically interacted at
the protein level. Immunoprecipitation analysis using HEK293
lysates (Figure 5A) showed that XFDL efficiently coprecipitated
with p53 (lane 4; human). Moreover, immunoprecipitation of en-
dogenous XFDL protein with HA-tagged Xenopus p53 was seen
from animal cap extracts (Figure 5B). In addition, a strong phys-
ical association was seen between in vitro-translated XFDL pro-
tein and recombinant GST-hp53 protein, indicating that the two
proteins directly interact (Figure 5C, top row). In contrast, GST-
hp53 did not bind to the unrelated multiple-Zn-finger proteins
SalF, Tsh3, and ROAZ (Figure 5C, bottom three rows; Onai et al.,
2004, 2007; Tsai and Reed, 1999).
We next tested whether XFDL modulates the binding of p53
to its target sequence in the gastrula animal cap. In a gel shift
assay, as previously reported (Luo et al., 2004), the extract con-
taining wild-type (WT) p53 (HA-tagged) induced only a faint band
shift of the probe (Figure 5D, lane 3) while constitutively active
p53 (p53-2KQ; mutated at the regulatory domain; described
later in Figure 6E) efficiently bound to the probe (Figure 5D,
lane 1). Injection of XFDL-MO substantially facilitated the bind-
ing of WT p53 to the probe (lanes 4 and 5), suggesting that en-
dogenous XFDL in the animal cap inhibits WT p53 from binding
to its target sequence (see the supershift with the HA antibody in
lane 6). Furthermore, in chromatin immunoprecipitation (ChIP)
assays of genomic DNA using the endogenous Mix.2 promoter
(Figure 5E), the specific binding of p53 to this site was aug-
mented by coinjection of XFDL-MO (compare lanes 3 and 4)
and suppressed by XFDL overexpression (compare lanes 2
and 3). In contrast, no obvious change was observed for the
Fast1 binding to theMix.2 promoter (Figure 5F). These observa-
tions demonstrate that endogenous XFDL protein negatively
regulates the target-specific DNA binding of p53 in presumptive
ectodermal cells.
XFDL’s Inhibitory Function on p53 Depends
on the Carboxy-Terminal Regulatory Domain of p53
The carboxy-terminal (C-terminal) region of p53 functions as a
regulatory domain (RD; Figure 6A; Bode and Dong, 2004). In-
deed, p53 lacking the RD has a stronger mesoderm-inducing ac-
tivity than does full-length p53 when injected into the animal cap
(Figure 6B, lanes 2 and 3; Cordenonsi et al., 2003; Takebayashi-
Suzuki et al., 2003). We found that this domain of p53 is essential
for the XFDL binding (Figure 6C, lanes 1 and 2). Furthermore,
mesodermal differentiation caused by the mutant p53 lacking
the RD (p53DRD) was not efficiently inhibited by coinjection of
XFDL (Figure 6D). The RD contains multiple lysine residues that
are acetylated by p300 (Figure 6E; Luo et al., 2004). The meso-
derm-inducing activity of p53 is impaired by an acetylation-resis-
tant replacement of the lysine residues (K-R) in the RD, whereas
it is enhanced by an acetylation-mimicking replacement (K-Q;
Luo et al., 2004) (Figure 6F). In an antiparallel manner, the binding
of XFDL to p53 increased and decreased upon the K-R and K-Q
replacements, respectively (Figure 6G). Importantly, the reduc-
tion of the mesoderm-inducing activity of p53 with the K-R
replacements could be reversed by XFDL-MO (Figure 6H, lanes
5 and 7). Taken together with the results shown in Figure 5D,
these findings indicate that XFDL is involved in the reduction of
p53 activity via the RD. It appears unlikely that XFDL actively
interferes with p53 acetylation by p300 since the acetylation level
of p53 in the animal cap is not strongly influenced by either XFDL
or XFDL-MO injection (Figure 6I).
The p53 deletion analysis (Figure S4A) showed that the amino-
terminal transactivation domain (TAD) was dispensable for the
binding to XFDL (Figure S4B, lane 6), while the rest (the C-termi-
nal portion) of the protein structure was necessary for the phys-
ical interaction (lanes 4 and 5). This indicates that, although the
RD plays a key role in the functional regulation by XFDL, a gross
protein structure in the C-terminal portion of p53 is required for
their strong physical interaction. In contrast, the short C-terminal
portion of XFDL (containing only the last two Zn-finger motifs;Figure S4C) was essential and sufficient for the binding to p53
(Figure S4D, lane 5 and arrow in Figure S4E, lane 6).
Mammalian XFDL-Related Zn-Finger Proteins
Inhibit p53 Activity
We next analyzed the specificity of XFDL among Zn-finger
proteins (Looman et al., 2002). SalF, Tsh3, (both Xenopus) and
ROAZ (mouse), which are Zn-finger proteins unrelated to XFDL,
did not bind to p53 in vitro (Figure 5C). Consistent with this,
p53-induced luciferase activity was reduced by coexpression
of XFDL but not by that of these unrelated Zn-finger factors
(Figure 7A). In the mouse genome database, we found two
multiple Zn-finger proteins (mZfp12 and mZfp74; Figure 7B)
that belong to the same subfamily as XFDL. They are strongly ex-
pressed in the early phases of neural differentiation of cultured
mouse ES cells (Sox1+ neural precursors; Watanabe et al., 2005)
but not in the maintenance culture (E-cadherin+ uncommitted
cells; Figure 7C and our unpublished data). Importantly, overex-
pression of each of them suppressed p53-luc activity as XFDL
did (Figure 7D, lanes 3–5). mZfp12 and mZfp74 bound to p53
protein (Figure 7E, lanes 7 and 8), and overexpression of
the two mouse factors inhibited mesodermal differentiation in
the Xenopus embryo (Figure 7F, two middle rows) and in the
Activin-treated (Figure 7G, lanes 3 and 4) and p53/p300-injected
animal caps (Figure 7H, lanes 3 and 4). These findings show that
the XFDL-subfamily molecules, but not the unrelated Zn-finger
proteins, have p53-binding and p53-inhibiting abilities.
DISCUSSION
Active Restriction of p53 Function by a Zygotic
Nuclear Factor Directs the Right Place and Time
for Ectoderm-versus-Mesoderm Specification
In this study, we identified the nuclear Zn-finger factor XFDL as a
zygotic suppressor of mesodermal differentiation in the pre-
sumptive ectoderm of Xenopus. The observation that XFDL con-
versely expands the expression of the pan-ectodermal marker
Foxi1a into the marginal zone (Figure 2R) indicates that XFDL
plays a pivotal role in the binary fate decision. XFDL counteracts
p53, which is essential for mesodermal differentiation (Corde-
nonsi et al., 2003, 2007; Takebayashi-Suzuki et al., 2003).
XFDL peaks at the onset of gastrulation (Figure 1E), when the
animal cap starts to lose its competence for mesodermal dif-
ferentiation. Importantly, when XFDL is blocked by XFDL-MO,
the animal cap remains competent for p53-induced mesoder-
mal differentiation even after the onset of gastrulation (Fig-
ure 4U). This point casts a light on the unanswered question
of whether the ubiquitous factor p53 (Hoever et al., 1994) plays
an instructive (active) role or just a permissive role in the germ-
layer specification; the requirement of XFDL shown here clearly
favors the former role. The present study has provided molecu-
lar evidence for a unique mode of p53 regulation: one antagonist
of p53 that acts by directly repressing its DNA-binding activity,
rather than promoting its degradation or modulating its activity
via acetylation or phosphorylation (Brooks and Gu, 2003;
Bode and Dong, 2004; Cordenonsi et al., 2007; Marechal
et al., 1997).Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc. 883
Figure 4. XFDL Antagonizes the Activation of Mesodermal Marker Genes by p53
(A–F) In situ hybridization analysis of early gastrulae. Side view. Control mRNA (250 pg/cell; A and D), human p53 (hp53; 50 pg/cell; B and E), or hp53 + 400 pg/cell
of XFDL (C and F) mRNAs were injected radially at the 4-cell stage.
(G) q-PCR analysis for Mix.2 expression. Control (lane 1), hp53 (lanes 2–5), hp300 (lanes 3–5), 100 pg/cell of XFDL (lane 4), and/or 400 pg/cell of XFDL (lane 5)
mRNAs were injected. Animal caps were prepared at stage 8.5 and harvested at stage 11.884 Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc.
Figure 5. XFDL Binds to p53 and Reduces p53’s Binding to Its Target Sequence
(A) Coimmunoprecipitation assay. The indicated expression plasmids were used to transfect into HEK293 cells. IP, immunoprecipitated; IB, immunoblot; FL,
Flag-tagged; HA, HA-tagged.
(B) Immunoprecipitation analysis in gastrula animal cap cells injected with mRNA of Xp53-HA (10 pg/cell; a subeffective amount that did not induce mesoderm-
alization).
(C) Pull-down experiment. [35S]-Methionine-labeled proteins were synthesized in vitro and incubated with GST (lane 1) or GST-hp53 (lane 2) bound to glutathione
Sepharose beads. Ten percent of each synthesized protein was applied as a loading control (lane 3).
(D) EMSA using the extracts of the animal caps (stage 10.5) injected with indicatedmRNAs (50 pg/cell each; see Figure 6E for hp53-2KQ-HA) and XFDL-MO (12.5
ng/cell for lane 4 and 50 ng/cell for lanes 5 and 6; top panel). Lane 6 shows the supershift using the anti-HA antibody. Asterisk: nonspecific binding. The bottom is
a western blot of overexpressed hp53.
(E) ChIP assay. Gastrula animal caps injected with XFDL mRNA (400 pg/cell; lane 2) or XFDL-MO (50 ng/cell; lane 4) were analyzed without (lane 1) or with an
anti-p53 antibody (lanes 2–4) (top row). Input genomic DNA was analyzed by PCR (second row). The relative ratio of the band intensity to lane 3 (after background
subtraction) was 0.13 (lane 2) and 7.98 (lane 4). RT-PCR analysis of the expression of p53 and ODC in each animal cap sample (third and fourth row) is shown.
(F) ChIP assay using anti-HA antibody (top). Fast1-HAmRNA (50 pg/cell) was injected with XFDL (lane 2) mRNA or XFDL-MO (lane 4). Analysis was performed as
in (E). Bottom shows a western blot with anti-HA antibody.(H–L) Double knockdown analysis of XFDL and p53. (H–K) Embryos injected with XFDL-MO (50 ng/cell; I and K) and/or p53-MO (50 ng/cell; J and K) were
harvested at stage 10.5 and analyzed by in situ hybridization with the Xbra probe. (L) q-PCR analysis using the animal cap. XFDL-MO (50 ng/cell; lanes 2–4 in
each panel) with p53-MO (12.5 ng/cell for lane 3 and 50 ng/cell for lane 4 in each panel) was injected and analyzed as in (G).
(M) The reporter constructs used in (N) to (S).
(N–T) Luciferase assays in the animal caps injected with hp53, hp300, and XFDLmRNAs. mRNAs (the same as in G) were coinjected with the indicated reporter
plasmids (50 pg/cell each). Animal caps were prepared as in (G) and dual-luciferase assays were performed. In (N), (P), (R), and (T), caps were treated with Activin
(5 ng/ml). Error bars represent the standard deviation (SD).
(U) q-PCR analysis for Mix.2 expression. GR-hp53 mRNA (50 pg/cell; lanes 2, 3, 5, and 6) was injected without (blue columns) or with (red columns) XFDL-MO
(50 ng/cell), and animal caps were prepared at the mid-gastrula stage (stage 8.5). Dexamethazone (Dex; 10 mg/ml) was performed from stage 8.5 to stage 10
(lane 3) or from stage 11 to stage 12 (lane 6).Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc. 885
Figure 6. The C-terminal Regulatory
Domain of p53 Is Involved in Both XFDL
Binding and XFDL-Mediated Inhibition
(A) The domain structure of hp53. TAD: transacti-
vation domain, DBD: DNA-binding domain, TD:
tetramerization domain, RD: regulatory domain.
(B) q-PCR analysis forMix.2 expression. Wild-type
hp53 or hp53DRD (50 pg/cell each) was coinjected
with hp300 (200 pg/cell). Animal caps were pre-
pared at the mid-blastula stage and harvested at
the mid-gastrula stage.
(C) Immunoprecipitation analysis was performed
using the lysates of the HEK293 cells transfected
with the indicated expression plasmids.
(D) q-PCR analysis for Mix.2 expression. hp53
(50 pg/cell; blue columns) or hp53DRD (50 pg/
cell; red columns) mRNA was injected and analy-
sis was performed as in panel (B).
(E) Schematic of the C-terminal regulatory
domain of hp53 (hp53RD) and its mutations. The
lysine residues in hp53RD were replaced with
arginine (R) or glutamine (Q) as indicated. WT:
wild-type.
(F) q-PCR analysis for Mix.2 expression. The indi-
cated mRNAs of p53-derived mutants (50 pg/
cell each) were coinjected with hp300 mRNA
(200 pg/cell; lanes 1–5). The animal cap assay
was performed as in (B).
(G) Immunoprecipitation assay with XFDL and the
p53-derived mutants. Analysis (top row) was per-
formed as in (C). Equal expression of each protein
was confirmed by western blot (with anti-FLAG
and anti-HA antibodies for the second and third
rows, respectively). Binding intensities in the top
row were quantified (bottom).
(H) q-PCR analysis for Mix.2 expression. The in-
jection and analysis were performed as in (B)
and (F).
(I) The acetylation status of hp53. mRNAs of
hp53-HA (50 pg/cell; lanes 2–7), hp300-HA
(200 pg/cell; lanes 3–7), FL-XFDL (100 pg/cell for
lane 4 and 400 pg/cell for lane 5), and XFDL-
MO (12.5 ng/cell for lane 6 and 50 ng/cell for
lane 7) were injected. Animal caps were prepared
as in (B) and subjected to western blots with the
indicated antibodies.In parallel to the XFDL system, the Smad pathway in the
presumptive ectoderm is negatively modulated by the maternal
factor Ectodermin (Dupont et al., 2005). In the marginal zone
(the presumptive mesoderm), local Nodal signals (Eimon and
Harland, 2002) activate the Smad pathway. A recent report has
suggested that Fgf signaling in the marginal zone (e.g., Fgf4)
promotes p53 phosphorylation via the MAPK-CK1 pathway
and thereby enhances the cooperative mesodermal differentia-
tion by p53 and Smad in the marginal zone (Cordenonsi et al.,
2007). The combination of these regulations (p53, XFDL,
Smad, and Fgf) seems to constitute a bi-stable relationship for886 Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc.the germ-layer specification: a dual-negative status (p53-off,
Smad-off) in the ectoderm and a dual-positive one (p53-on,
Smad-on) in the marginal zone.
In fact, several other mechanisms (both maternal and zygotic)
have been implicated in the negative regulation of the Smad
signals in the animal cap, including Smurf, Smad6/7, Coco, and
Sox3 (Bell et al., 2003; Nakayama et al., 2001; Zhang et al., 2001;
Zhang and Klymkowsky, 2007). Probably because of these,
XFDL-MOalonedoes not clearly elongate thecompetenceperiod
of theanimal cap formesodermal inductionbyActivin (FigureS6A;
the same is the case for the induction by Fgf; Figure S6B).
Figure 7. XFDL-Related Zn-Finger Proteins Antagonize p53 Activity
(A) Luciferase assay usingmammalian H-1299 cells. Cells were harvested 24 hr after transfection with p53-luc, phRL-null, and the indicated expression plasmids.
(B) Domain structure ofmZfp12 andmZfp74 andROAZ. Blue filled circles: Zn-fingermotifs. InmZfp12 andmZfp74, the amino-terminal regions contain a Kru¨ppel-
associated box, which is missing in XFDL.
(C) q-PCR analysis for the expression ofmZfp12 andmZfp74. Undifferentiated mouse ES cells (lane 1) and differentiating ES cells (cultured by the SFEBmethod;
Watanabe et al., 2005), E-cadherin+/Sox1 cells (uncommitted or non-neural), and E-cadherin/Sox1+ cells (neural) were collected by FACS and analyzed by
q-PCR (normalized by b-actin expression).
(D) Luciferase assay in H-1299 cells. Cells were transfected with p53-luc and the indicated expression plasmids.
(E) Coimmunoprecipitation analysis of mammalian XFDL-related proteins (Venus-fused) and hp53 (HA-tagged) using HEK293 cells. Asterisks: nonspecific bands.
(F–H) Activities of mammalian XFDL-related genes in Xenopus. (F) Control (top row), mZfp12 (second row), mZfp74 (third row), or ROAZ (bottom row) mRNA
(400 pg/cell each) was injected into Xenopus and analyzed as in Figures 2D and 2F. Vegetal view. (G) q-PCR analysis for Mix.2 expression. Xenopus embryos
were injected with the indicated mRNAs (400 pg/cell each) and animal caps were analyzed as in Figure 2A. (H) q-PCR analysis forMix.2 expression in the animal
cap. mRNAs of mammalian XFDL-related genes were coinjected with hp53 (50 pg/cell) and hp300 (200 pg/cell) (lanes 2–5). Analysis was performed as in
Figure 4G.Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc. 887
XFDL expression in the animal cap is not downregulated by
Activin (our unpublished data), suggesting that the ectoderm-
specific expression of XFDL is not simply due to the lack of
TGF-b signals in the animal cap. Two ectoderm-specific tran-
scription factors, Foxi1e and XLPOU91 (Mir et al., 2007; Snir,
et al., 2006; neither binds to p53; our unpublished data), do not
seem to lie upstream of XFDL expression either; the injection
of neither Foxi1e nor XLPOU91 upregulates XFDL expression
(our unpublished data; in addition, their transcripts start to
be expressed in the ectoderm clearly after the onset of XFDL
expression).
Differential Effects of XFDL on Fast-Independent
and -Dependent AREs
Previous studies have indicated that ‘‘ARE’’ can be generally
classified into the Fast-independent (reviewed in Wardle and
Smith, 2006) and Fast-dependent (Watanabe and Whitman,
1999) types. The distal-element ARE activity of the goosecoid
promoter is a typical pure reporter of Smad2 activity and does
not depend on Fast, whereas theMix.2 ARE belongs to the latter
type. We found (rather unexpectedly) that, unlike the distal-ele-
ment ARE activity of the goosecoid promoter, the activity of the
ARE reporter derived from theMix.2 promoter (pARE(Mix.2)-luc;
Chen et al., 1996, 1997; Cordenonsi et al., 2003; Figure S7A) is
inhibited by XFDL, although this pARE(Mix.2)-luc reporter neither
responds to p53 activity nor contains any p53-binding site (Fig-
ures S7B–S7D).
We therefore examined the effect of XFDL on Fast gene
expression (Figure S8) and found that XFDL substantially de-
creases the expression of Fast1 and Fast3 in the stage 11 animal
cap (Figures S8J, S8M, and S8O). This suppression of Fast
genes by XFDL seems to explain, at least in part, why XFDL
inhibits pARE(Mix.2)-luc activity but not DE(4x)-luc activity. This
idea of the secondary (not primary) effect of XFDL is strongly
supported by the observations that coinjection of Fast1 (which
keeps Fast1 expression high) makes pARE(Mix.2)-luc activity
insensitive to XFDL (Figure S7F; similar effects are seen for the
Mix.2 reporter with point mutations in the p53-binding site; Fig-
ure S7H). In contrast, Fast1 coinjection does not affect XFDL’s
inhibition of the activity of WT Mix.2-luc, which involves both
an ARE and a p53-binding element (Figure S7E).
Taken together with theDE(4x)-luc data (Figure 4T), these find-
ings demonstrate that the p53-binding element plays a primary
role in the direct inhibition of the Mix.2 promoter by XFDL.
XFDL-Related Factors Share Similar Functions
The vertebrate genome contains a large number of diverse
multiple-Zn-finger proteins. Unlike multiple-Zn-finger proteins
diverse from XFDL, the XFDL-related mouse Zn-finger proteins
(mZfp12 and 74; expressed during early neuroectodermal differ-
entiation of mouse ES cells) bind to p53 and suppress p53-luc
activity in the cotransfection assay using mammalian cells (Fig-
ures 7D and 7E). Moreover, when overexpressed, they can in-
hibit mesodermal differentiation in the Xenopus embryo and in
the animal cap treated with Activin or injected with p53/p300
(Figures 7F–7H). These findings indicate that the p53-inhibiting
function is shared by XFDL-related Zn-finger proteins but not
necessarily by multiple-Zn-finger proteins in general.888 Cell 133, 878–890, May 30, 2008 ª2008 Elsevier Inc.Whether the mammalian germ-layer specification involves
a mechanism similar to that in Xenopus is an important and chal-
lenging research topic. Given that a recent report has suggested
an essential role of p53 in an early phase of mouse ES cell differ-
entiation (Lin et al., 2005), a conserved mechanism of vertebrate
ectodermal specification involving Zn-finger proteins and p53 is
an attractive hypothesis, which should be functionally tested by
various approaches including gene targeting.
EXPERIMENTAL PROCEDURES
Functional Screening
A cDNAplasmid library was constructed from stage 11.5 animal caps using the
pBluescript SK () vector. Each colony with an insert was cultured individually
in the well of a 96-well plate. For the initial screen, synthetic RNAwas prepared
from each pool of mixed 96 clones by the mMessage mMachine kit (Ambion).
Ten nanograms of mRNA per pool was injected into all the animal blastomeres
at the 8-cell stage. Animal caps were excised at the mid-blastula stage (stage
8.5), incubated until stage 11 (equivalent) with 5 ng/ml of Activin, harvested,
and analyzed for Xbra expression by q-PCR (ABI, model 7500; normalized
by ODC/ornithine decarboxylase expression). Twenty pools showed inhibitory
effects (down to <50%) and were subjected to sib screening.
Embryonic Manipulation, Expression Analysis, and Cell Culture
4- or 8-cell embryos were injected with synthetic mRNAs using a fine glass
capillary and a pneumonic pressure injector (Narishige). Excised animal
caps were cultured in 13 LCMR supplemented with 0.2% BSA until given
stages. Whole-mount in situ hybridization analysis was performedwith DIG-la-
beled antisense RNA probes. For immunohistochemistry, animal caps were
sectioned at 10 mm increments. RT-PCR and western blot analyses were per-
formed as described (Sasai et al., 2004). For luciferase assays, the promoter
regions of Mix.2 and Gsc were amplified by PCR and inserted into the pGL3
enhancer vector (Promega) (pMix.2-luc, pMix.2-AREmut-luc, and DE(4x)-luc;
Cordenonsi et al., 2003; Chen et al., 1996; Watabe et al., 1995). p53-luc (con-
taining 14 repeats of a p53-binding element of theMuscle Creatin Kinase pro-
moter) was purchased from Stratagene. The luciferase activity of each sample
was normalized by the activity of coinjected (or cotranfected) phRL-null (Prom-
ega). Injection experiments were performed at the 4-cell stage for whole-
mount analyses and at the 8-cell stage for animal cap assays. GFP was
used as the control neutral RNA. Primer sets for RT-PCR (Figure 5E) and
q-PCR are shown in Table S1. The expression of each gene was normalized to
the FGFR1 expression (Figure 1E) or ODC expression (the other experiments).
The design of MOs is described in Supplemental Experimental Procedures.
Unless otherwise stated, human p53 (Bode and Dong, 2004) and human
p300 (Bellefroid et al., 1997) were used in this study because of the availability
of good specific antibodies (for instance, those for acetylated p53). Xenopus
p53 and human p53 exhibit similar mesoderm-inducing activities (Figure S7I),
which are inhibited by XFDL (not shown). Transfection experiments using
H-1299 (lacking active p53; Luo et al., 2004; Cordenonsi et al., 2007) and
HEK293 cells were performed with pCS2-based expression plasmids. Cells
were harvested 24 hr after transfection and lysed with TNEB buffer (150 mM
NaCl, 5 mM MgCl2, 10 mM Tris-HCl [pH 7.8], 1 mM EDTA, 0.5% NP-40) with
protease inhibitors. To raise anti-XFDL156 antiserum, bacterially expressed
recombinant XFDL156 (amino acid residues 1–250; GST-fused) was used to
immunize rats. FACS sorting of undifferentiated and differentiating mouse
ES cells (Sox1-GFP ES cells; a kind gift of Dr. Austin Smith) was performed
as described previously (Watanabe et al., 2005).
Immunoprecipitation, Pull-down, ChIP, and EMSA
Immunoprecipitation assays were performed with protein G Sepharose (GE
Healthcare) and subsequently analyzed by western blot. Antibodies used
in this study were anti-FLAG, anti-HA (Sigma), anti-Smad2 (Cell Signaling
Technology), anti-Phospho-Smad2 (Calbiochem), anti-Acetyl-p53 (Upstate
Biotechnology), and anti-p53 (clone X-77; Santa Cruz Biotechnology). Pull-
down experiments using glutathione Sepharose were performed as described
previously (Cordenonsi et al., 2003). Successful production and purification
of GST-fused proteins were confirmed by SDS-PAGE and CBB staining
(data not shown). In vitro protein synthesis was performed by using the TNT
transcription/translation kit (Promega) in the presence of [35S]-Methionine
(GE Healthcare).
ChIP (Stewart et al., 2006) and EMSA (Germain et al., 2000;Wolkowicz et al.,
1995) assays were performed as described.
SUPPLEMENTAL DATA
Supplemental data include Experimental Procedures, eight figures, and one
table and can be found with this article online at http://www.cell.com/cgi/
content/full/133/5/878/DC1/.
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